<DOC>
	<DOCNO>NCT01939418</DOCNO>
	<brief_summary>This study consist two part . In phase Ib part , investigator explore recommend dose gemcitabine , cisplatin , RAD001 combination patient metastatic TNBC . After complete phase Ib part , investigator review data discus Novartis start phase II part . In phase II part , investigator compare efficacy gemcitabine cisplatin without RAD001 patient metastatic TNBC .</brief_summary>
	<brief_title>Phase Ib/II Trials RAD001 Triple Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>PIK3CA active mutation frequent genetic event breast cancer , include TNBC present activate PI3K/AKT signal due PIK3CA mutation PTEN deficiency . TNBC cell line activate PI3K/AKT signal show high sensitivity PI3K/mTOR inhibitor . RAD001 potent mTOR complex 1 inhibitor show enhance cisplatin gemcitabine induce apoptosis inhibit p53 induce p21 expression . This study consist two part . In phase Ib part , investigator explore recommend dose gemcitabine , cisplatin , RAD001 combination patient metastatic TNBC . After complete phase Ib part , investigator review data discus Novartis start phase II part . In phase II part , investigator compare efficacy gemcitabine cisplatin without RAD001 patient metastatic TNBC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Females histologically confirm , metastatic stage IV breast cancer ER/PgR negative poor ( Allred score ≤ 3/8 ) HER2 negative breast cancer ECOG performance status 02 Age ≥ 20 year Previously treat anthracycline taxane adjuvant/neoadjuvant metastatic setting ≤ 2 chemotherapy regimen metastatic disease Radiological objective evidence recurrence progression last systemic therapy prior enrolment . CNS metastasis permit asymptomatic requiring treatment steroid document nonprogressing study entry Presence measurable evaluable disease RECIST 1.1 criterion Adequate hematopoietic function : Absolute granulocyte count ≥1,500/mm3 , platelet ≥100,000/mm3 , hemoglobin ≥ 10g/mm3 Adequate hepatic function : total bilirubin ≤ 1.5 x upper normal limit ( UNL ) , AST/ALT ≤2.5 x UNL ≤5 x UNL present hepatic metastasis Fasting serum cholesterol ≤ 300mg/dl fasting triglyceride ≤ 2.5 x UNL Adequate renal function : Serum creatinine ≤1.5mg/dL Patients sign write informed consent study entry Patients positive HBVDNA HBsAg screen must initiate prophylaxis appropriate antiviral medication least one week prior treatment start Known active CNS metastasis Patients receive prior therapy gemcitabine Patients nonmeasurable lesion bone metastasis ( e.g . pleural effusion , ascites ) . Patients 3 prior chemotherapy line treat metastatic breast cancer . Patients receive prior therapy mTOR inhibitor PI3K inhibitor Known hypersensitivity mTOR inhibitor , e.g . Sirolimus ( rapamycin ) . Radiotherapy within four week prior enrolment , except radiotherapy bone analgesic purpose lytic lesion risk fracture . Patients must recover radiotherapy toxicity prior enrolment . Patients history cancer situ uterine cervix cancer nonmelanotic skin cancer Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral everolimus Active ulceration upper gastrointestinal tract Other concurrent severe and/or uncontrolled condition ( e.g . uncontrolled diabetes mellitus , active untreated uncontrolled infection , chronic obstructive chronic restrictive pulmonary disease include dyspnea rest cause ) could cause unacceptable safety risk compromise compliance protocol . Patients known history HIV seropositivity . Screening HIV infection baseline require . Significant symptomatic deterioration lung function . If clinically indicate , pulmonary function test include measure predict lung volume , DLco , O2 saturation rest room air consider exclude restrictive pulmonary disease , pneumonitis pulmonary infiltrates . Patients treat drug recognize strong inhibitor inducer isoenzyme CYP3A enrolment ( rifabutin , rifampicin , clarithromycin , ketoconazole , itraconazole , voriconazole , ritonavir , telithromycin ) continuously least 7 day time period last 2 week prior enrolment Known hypersensitivity protocol treatment Pregnant breast feed Peripheral neuropathy ≥ grade 2 ( NCI CTCAE version 4.0 ) randomization Patients unwilling unable comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>triple negative breast cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>RAD001</keyword>
</DOC>